NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology (ESMO) Annual Congress and the Ongoing Phase 1b Trial of NGM120 in Patients with Advanced Pancreatic Cancer at the American Association for Cancer Research (AACR) Special Conference: Pancreatic Cancer
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that abstracts related to NGM120, an antagonist antibody product candidate that binds GFRAL and is designed to inhibit GDF15 signaling, have been accepted for presentation at the ESMO Annual Congress, which will take place September 9 – 13, 2022 at the Paris Expo Porte de Versailles, Paris, and at the AACR Special Conference: Pancreatic Cancer, which will take place September 13 – 16, 2022 at the Sheraton Boston Hotel, Boston.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.